Within Bertin Pharma Branch,
Ellipse Pharmaceuticals provides SMART Innovation & Pharmaceutical Development Services for New Chemical Entities and Biotech-derived drugs. Our services include
Preformulation and
Formulation of new therapeutic actives adapted to the clinical development stage,
Generic or Generic Plus formulations,
Life Cycle Management strategies, Process
troubleshooting and manufacturing
technical assistance.
Ellipse Pharmaceuticals has developed specific expertise and know-how in the following: Modified release formulations including Multiple units systems, Parenteral formulations (IR, SR – liquid & freeze-dried), micro/nano-emulsion systems, patented formulations for mucosal application.
A new member joins Bertin Pharma Branch
|
IDPS (Institut de Développement des Produits de Santé) joins Bertin Pharma Branch completing that way services proposed by
SPI-Bio,
Biotec Centre and Ellipse Pharmaceuticals.
This new acquisition permits to reinforce Ellipse Pharmaceutical competences and resource with a comprehensive and integrated offer:
from early steps in formulation and analytical development to manufacturing and distribution of clinical batches, for new biochemical entities, proteins and highly potent products.
Thanks to its GMP facilities and with two GLP laboratories,
Bertin Technologies pharmaceutical branch offers now access to a larger range of services: pharmaceutical development, clinical batch manufacturing, ADME/bioanalysis, pharmacology, biotransformation and biomarkers.
With a current turnover over 12 M€ for 100 people, Bertin Pharma confirm its will to become a solid partner for pharmaceutical R&D.
